Philippe Pouletty, M.D., is Founder and Chairman of Abivax and Co-founder and CEO of Truffle Capital. Dr. Pouletty has a strong background in Europe and the United States (including Silicon Valley) and is a pioneer in the biotechnology and medical devices sector. As an entrepreneur, he founded/co-founded among others: Carmat, Deinove, Abivax, Pharnext, Vexim — Truffle portfolio companies. As an inventor, Dr. Pouletty has filed 32 patents, one of which is the second-highest revenue generator in life sciences for Stanford University, earning him membership in Stanford’s prestigious Invention Hall of Fame in 2012. Dr. Pouletty was Chairman of France Biotech from 2001 to 2009, and has held the title of Honorary Chairman since 2009. He conceived the Jeune Entreprise Innovante (JEI) program to boost the development of young and innovative companies in France. Philippe Pouletty is a medical doctor, former resident in haematology and immunology in Parisian hospitals, and was a postdoctoral researcher (1986-1988) at Stanford University. He was the 1999 winner of the American Liver Foundation award. Dr. Pouletty has been awarded Chevalier de la Légion d’Honneur.
Interview with the CEO and the Chairman: Abivax (OTCMKTS:AAVXF)
September 22, 2020